23andMe Board Explores Strategic Alternatives Amid Restructuring
23andMe Holding Co. ( ME, Financials) announced that its board's Special Committee is reviewing strategic alternatives, including a potential sale, business combination, asset sales, restructuring, or other options, the company said in a statement.
Veradigm ends exploration of strategic alternatives without deal
Veradigm (MDRX) announced that its board of directors completed its previously announced review of strategic alternatives. “Throughout the
23andMe is exploring strategic alternatives, looking to raise capital
23andMe said it's started exploring strategic alternatives, including a possible sale. The company released third-quarter results that showed an 8% drop in consumer services revenue year over year. 23andMe said it will "need additional liquidity" to fund its operations, and it is looking to raise additional capital.
Veradigm Concludes Exploration of Strategic Alternatives and Announces Operational Review
Veradigm® (OTCMKTS: MDRX), a leading provider of healthcare data and technology solutions, announced today that the Veradigm Board of Directors (the "Board") completed its previously announced review of strategic alternatives to maximize stockholder value.
23andMe announces exploration of strategic alternatives
The Special Committee of the board of 23andMe Holding Co. announced that it has undertaken a process to explore strategic alternatives, including, among other alternatives, a poss
Veradigm ends strategic review after no firm bids
Veradigm (OTC:MDRX) said that it's ending a strategic review after it received no firm proposals in its process. The electronic medical records firm disclosed that five bidders made preliminary, non-biding indications of interest,
The Business Journals3d
Genetic test maker 23andMe eyes strategic alternatives, including a sale
CEO Anne Wojcicki last spring proposed buying out the company and taking it private. Genetic testing pioneer 23andMe is looking at strategic alternatives, including a possible sale, it said ...
Morningstar7d
Strategic Advisers Alternatives FSLTX
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
FiercePharma4d
No deal: Sage rejects Biogen's buyout offer, scouts for strategic alternatives
After receiving and considering an "unsolicited" buyout offer from partner Biogen, Sage Therapeutics is kicking the tires on ...